Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Capitalistaon Jun 19, 2023 10:24am
117 Views
Post# 35503250

RE:RE:RE:RE:RE:RE:AA and mBC

RE:RE:RE:RE:RE:RE:AA and mBCNoteable, in which subset of HR+ HER- mBC treatment situations are you saying paclitaxel is the SOC?  My research shows nowadays it's used mainly when patients have progressed after CDK4/6 inhibitor treatment, or in the 20% of patients who don't respond to CDK4/6.  This would imply that CDK4/6 is the SOC.  

As I recall, the BRACELET-1 PFS numbers reported at ASCO were roughly equal to those exhibited in CDK4/6 treatments.  Problem is, most mBC patients eventually develop resistance to CDK4/6 and have to transition to other treatments.  
<< Previous
Bullboard Posts
Next >>